Authors' recommendations: Low quality evidence of shows that the use of olaparib in ovarian cancer did not show changes in overall survival. In patients with high-grade serous ovarian cancer, the use of olaparib as maintenance therapy after platinum-sensitive relapse, might improve progression-free survival, especially in patients with BRCA mutations (approximately four versus seven months). In patients with recurrent platinum-sensitive or resistant epithelial ovarian cancer who received three or more lines of chemotherapy, the use of olaparib as therapy would be associated to a higher rate of response. There is no consensus on the indications recommended by the clinical practice guidelines consulted and on the indications approved by the different regulatory agencies either, although its indication as maintenance monotherapy after second-line chemotherapy in patients with platinum-sensitive, high-grade serous ovarian cancer with BRCA 1 or BRCA 2 mutation shows wider consensus.

Project Status: Completed

Year Published: 2017

URL for published report: www.iecs.org.ar/home-ets/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Argentina

Organisation Name: Institute for Clinical Effectiveness and Health Policy

Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA

Contact Name: info@iecs.org.ar

Contact Email: info@iecs.org.ar

Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)